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Abstract
Background: Smoking is a leading cause of preventable death. Early studies based on
samples of twins have linked the lifetime smoking practices to genetic predisposition.
The flavin-containing monooxygenase (FMO) protein family consists of a group of enzymes that metabolize drugs and xenobiotics. Both FMO1 and FMO3 were potentially
susceptible genes for nicotine metabolism process.
Methods: In this study, we investigated the potential of FMO genes to confer risk of
nicotine dependence via deep targeted sequencing in 2,820 study subjects comprising
1,583 nicotine dependents and 1,237 controls from European American and African
American. Specifically, we focused on the two genomic segments including FMO1,
FMO3, and pseudo gene FMO6P, and aimed to investigate the potential association
between FMO genes and nicotine dependence. Both common and low-frequency/rare
variants were analyzed using different algorithms. The potential functional significance
of SNPs with association signal was investigated with relevant bioinformatics tools.
Results: We identified different clusters of significant common variants in European
(with most significant SNP rs6674596, p = .0004, OR = 0.67, MAF_EA = 0.14, FMO1)
and African Americans (with the most significant SNP rs6608453, p = .001, OR = 0.64,
MAF_AA = 0.1, FMO6P). No significant signals were identified through haplotype-
based analyses. Gene network investigation indicated that both FMO1 and FMO3
have a strong relation with a variety of genes belonging to CYP gene families (with
combined score greater than 0.9). Most of the significant variants identified were
SNPs located within intron regions or with unknown functional significance, indicating
a need for future work to understand the underlying functional significance of these
signals.
Conclusions: Our findings indicated significant association between FMO genes and
nicotine dependence. Replications of our findings in other ethnic groups were needed
in the future. Most of the significant variants identified were SNPs located within intronic regions or with unknown functional significance, indicating a need for future
work to understand the underlying functional significance of these signals.
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1 | INTRODUCTION

Three protein families are involved in nicotine pharmacokinetics:
liver cytochrome P450 enzymes (CYPs), flavin-containing monooxy-

Smoking is a leading cause of preventable death, causing about 5 mil-

genases (FMOs), and uridine diphosphate glucuronosyltransferase en-

lion premature deaths worldwide each year, and current trends show

zymes (Bloom et al., 2013). The FMO protein family consists of a group

that tobacco use will cause more than 8 million deaths annually by 2030

of enzymes that metabolize drugs and xenobiotics (Krueger & Williams,

(WHO, 2013). Strong evidence connects cigarette smoking and lung

2005). Five forms of FMOs are found in human and have been desig-

cancer (Biesalski et al., 1998; Doll & Hill, 1954; Doll, Peto, Boreham,

nated FMO1–FMO5 (Krueger & Williams, 2005). Among these FMO

& Sutherland, 2004; Hecht, 2012), and according to the data from

genes, part of nicotine inhaled during smoking can be broken down to

American cancer society, lung cancer causes the most death each year

N′-oxide by FMO 3 (encoded by FMO3) (Bloom et al., 2013). Hinrichs

compared to other cancers (Shafey, Eriksen, Ross, & Mackay, 2009).

et al. (2011) has identified significant association between SNPs of

In addition, cigarette smoking is also the principal environmental risk

FMO1 and nicotine dependence. Although a recent study has shown

factor for developing chronic obstructive pulmonary disease, a dis-

that common polymorphisms in FMO3 can influence nicotine clearance

ease characterized by chronically poor airflow (Kennedy, Chambers,

(Bloom et al., 2013), no study has provided direct evidence of the as-

Du, & Dimich-Ward, 2007; Laniado-Laborín, 2009; Tønnesen, 2013).

sociation between FMO3 polymorphisms and nicotine dependence.

Therefore, understanding the underlying biological mechanisms of nic-

Except for these five forms of FMOs found in human, FMO6P, which is a

otine dependence will still have huge public health significance in the

pseudo gene located very near to FMO3, is reported to have significant

future.

sequence homology with FMO3 (Hines, Hopp, Franco, Saeian, & Begun,

Early studies based on samples of twins have linked the life-

2002). To sum up, both FMO1 and FMO3 were potentially susceptible

time smoking practices to genetic predisposition (Carmelli, Swan,

genes for nicotine metabolism process and further studies were still

Robinette, & Fabsitz, 1992). A meta-analysis of the data from five stud-

needed to investigate the underlying variants within these genes that

ies, each involving more than 1,000 twin pairs, showed an estimated

are associated with the susceptibility of nicotine dependence.

heritability of 60% for the propensity to smoke (Vink, Willemsen, &

In this study, we investigated the potential of FMO genes to confer

Boomsma, 2005). The followed linkage and gene association mapping

risk of nicotine dependence via deep targeted sequencing in 2,820

studies have identified several susceptible loci, including genes en-

study subjects (1,432 European and 1,388 African Americans) com-

coding dopamine transporter/receptors (Huang et al., 2008; Lerman

prising 1,583 nicotine dependents and 1,237 controls. Specifically, we

et al., 1999; Sabol et al., 1999), cholinergic receptors (Feng et al.,

focused on the two genomic segments including FMO1, FMO3 (pro-

2004; Hong et al., 2010; Saccone et al., 2006; Thorgeirsson et al.,

tein coding genes for FMO 1 and 3), and FMO6P (pseudo gene), and

2010), taste receptor (Mangold, Payne, Ma, Chen, & Li, 2008), sero-

aimed to investigate the potential association between FMO genes

tonin receptor (Gerra et al., 2005; Kremer et al., 2005), and gamma-

and nicotine dependence. Via implementing targeted sequencing,

aminobutyric acid type B receptor (Beuten et al., 2005), that are

we are interested to figure out that whether rare variants contribute

associated with nicotine dependence. The breakthrough of microar-

to the association signal derived from common variants. In addition,

ray technology at the end of 20th century enabled the “unbiased”

comparisons were made between the association results based on

association mapping analysis in the whole human genome. Genome-

European Americans and African Americans.

wide association study (GWAS), which scans the whole genome by
capturing the information of common SNPs, has been proved informative for nicotine dependence (Bierut et al., 2007; Liu et al., 2009;

2 | METHODS

Thorgeirsson et al., 2008; Uhl et al., 2007), and greatly accelerates
the progress of this gene hunting process. Nevertheless, GWAS

This research was reviewed and approved by the Institutional Review

only focuses on a set of preselected, generally common SNPs, and

Board at Washington University in Saint Louis. All the study subjects

tends to omit the rare variants and structural variants such as short

provided informed consent.

insertion and deletions (indels). The recent development of “next-
generation” sequencing technology has enabled researchers to investigate these variants which are not covered in GWAS at a relatively

2.1 | Study subjects and sample ascertainment

lower genotyping cost (Hall, 2007; Quail et al., 2012; Tucker, Marra,

Study subjects were recruited from Collaborative Genetics Study of

& Friedman, 2009). A recent published study focusing on targeted se-

Nicotine Dependence and the Genetic Study of Nicotine Dependence

quencing data of CHRNA5 has identified several novel rare and low-

in African Americans (Bierut et al., 2007; Saccone et al., 2006). A total

frequency coding variants that contributed to nicotine dependence

of 2,820 individuals comprising 1,432 European Americans and 1,388

(Olfson et al., 2015).

African Americans were examined in our study. We assessed the

|
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study subjects’ smoking behavior using Fagerström test for nicotine

from combined, European American, and African American sample

dependence (FTND; Heatherton, Kozlowski, Frecker, & Fagerström,

set, respectively. Sixty-four variants with functional significance (non-

1991). The nicotine dependence patients were defined as current

synonymous/stop–gain variants or frameshift indels) were identified

smokers with FTND score equal or greater than 4, and controls were

(Table S1).

defined as having FTND score of 0 or 1 and have smoked at least 100
cigarettes in their lifetime (Table 1).

Variants satisfying the following criteria were utilized in variant-
level analysis: (1) variants with MAF > 0.05 and (2) located within targeted gene regions or the linkage disequilibrium (LD) blocks that are

2.2 | Targeted sequencing of FMO1 and FMO3

(partly) overlapped with the targeted gene regions (detailed definition
of blocks is given below). The association analysis was conducted by

DNA samples were extracted from blood with Puragene. Targeted

fitting logistic regression model. The genotypic data were coded in

sequencings on two 100 kb regions of FMO1 and FMO3 were per-

additive model. This analysis was performed in combined, European

formed at the Center for Inherited Disease Research. These genomic

American, and African American individuals separately (for combined

regions also contain part of gene FMO4 and a whole pseudo gene

subjects, we tested a union of SNPs sets selected based on European

FMO6P. The quality control was implemented in samples and variants

American and African American subjects). Gender and age were in-

level, respectively. The mean on-target coverage was 180× for each

cluded as covariates in all the three analyses. The first two principal

sequencing experiment and greater than 96% of on-target bases had

components based on the three sample sets were also utilized as co-

a depth greater than 20×. Full detailed description of genotyping and

variates accounting for the potential population stratification when

quality control process can be found in Supplemental Methods.

fitting the logistic models. To address the multiple comparison problem, we implemented Bonferroni correction. The number of tests was
calculated in the following way:

2.3 | Statistical analysis
A total of 1,432 European Americans and 1,388 African Americans
with targeted sequencing of FMO1 and FMO3 were examined.
General data analyses were performed by R (R i386 3.2.1; Ripley,
2001). To quantify the potential population stratification, we conducted principal component analysis (PCA) in the combined sample
(115,338 markers), as well as separately in the European American
sample (154,049 markers) and African American sample (218,399
markers), using a previous collected genome-wide array dataset containing 950,847 SNPs (Price et al., 2006). Population genetics software STRUCTURE was utilized to conduct PCA (Pritchard, Stephens,
& Donnelly, 2000). Sequencing data were annotated by sequencing
data annotation software Annovar (Wang, Li, & Hakonarson, 2010).
We have implemented a comprehensive approach for the quality control of our targeted sequencing data and detail information and the
criteria used can be found in supplemental methods. After variant-
level quality control, 5,105, 2,600, and 3,817 variants located within
the two targeted genomic regions (FMO1/FMO3) were extracted
TABLE 1

N = n1 + n2 ,
where for each dataset, n1 stands for the number of LD blocks
generated by this dataset and n2 is the number of variants that do not
belong to any LD blocks. In addition to testing associations for single
variants, we also conducted haplotype-based analysis with combination of multiple variants in European American and African American
datasets, respectively. LD blocks were constructed using the default
algorithm taken from Gabriel et al. (2002). On D′, 95% confidence
bounds are generated and each comparison is called “strong LD”
when the confidence bounds have upper bound ≥0.98 and lower
bound ≥0.7, and a block is created if 95% of informative comparisons
are “strong LD.” Variant-level association analysis and LD construction and haplotype analyses were conducted using Plink (Purcell et al.,
2007). Bonferroni correction was also applied to haplotype-based
analyses. Six haplotypes were constructed and tested in European
Americans (Tables S7), while 20 haplotypes were constructed and
tested in African Americans (Tables S7). The p-value thresholds used
for European Americans and African Americans were .008 and .0025,
respectively.

Characteristics of study subjects

Variants were then classified into two categories for the gene-level
analysis (mostly rare variants). The two categories are: (1) gene-region

Nicotine dependent

Nondependent

1,583

1,237

Female

901 (59)

805 (65)

Male

682 (41)

432 (35)

European American

730 (46)

702 (57)

for the gene-level analysis. Same as the variant-level analysis, we also

African American

853 (54)

535 (43)

conducted this analysis in combined, European American, and African

Sample, n
Gender (%)

Ethnicity (%)

Age in year, mean (range)
FTND score, mean (range)

37 (25–45)
6.34 (4–10)

FTND, Fagerström test for nicotine dependence.

36 (25–45)
0.16 (0–1)

variants set (i.e., the variants located within the gene region) and
(2) functional-region variants (variants located within regions with significant functional significance, including exonic regions, 3′/5′ UTR,
smaller comparing to gene-region set). For these two variants sets,
analysis was performed on variants with MAF less than 0.01 and 0.05.
Both SKAT and weighted burden test (Lee et al., 2012) were utilized

American individuals separately. Gender, age, and first two PCs based
on the three sample sets were also included as covariates. LocusZoom
was utilized to make regional association plots (Pruim et al., 2010).
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sample set, respectively. LD blocks were constructed in European

2.4 | Bioinformatics analysis

American and African American sample sets (Tables S2 and S3). Based

We examined the targeted SNPs and/or genes using several bioin-

on these LD blocks patterns, the significant thresholds for variant-

formatics tools and databases. We utilized the protein–protein in-

wise analysis were 3.6 × 10−3 and 1.25 × 10−3 in European American

teraction database STRING (http://string-db.org/; Szklarczyk et al.,

and African American sample set, respectively. We chose the most

2015) to explore the potential interactions of our targeted genes. The

conservative one as our p-value threshold in the analysis (1.25 × 10−3).

Regulome DB (http://regulomedb.org/; Boyle et al., 2012) was used

Multiple different significant variants were identified in European

to predict the potential functional consequences of the identified risk

American and African American datasets (Table 2, Figure 1). A clus-

SNPs. This database is a web-based bioinformatics tool integrated

ter of significant variants were identified in European American indi-

with multiple types of data (including ChIP-seq, DNase-seq, eQTLs,

viduals (with most significant SNP rs6674596, p = .0004, OR = 0.67,

etc.) from the Encyclopedia of DNA Elements (ENCODE) project (Xie

FMO1). In African American individuals, we identified several clus-

et al., 2013).

tered significant variants (with the most significant SNP rs6608453,
p = .001) in pseudo gene FMO6P. The full results of variant-wise association analysis were summarized in Tables S4–S6.

3 | RESULTS
3.1 | Variant-wise association of FMO genes and
nicotine dependence

3.2 | Haplotype-based and gene-wise association of
FMO genes and nicotine dependence

Variants (270, 326, and 368) were selected for variant-wise associa-

We performed haplotype-based analyses in European American and

tion analysis in European American, African American, and combined

African American dataset separately. The p-value thresholds were

TABLE 2

Significant signals in variant-wise association analysis

CHR

VAR

GENE

POS

A1

OR_EA

p_EA

MAF_EA

OR_AA

p_AA

MAF_AA

1

rs11812044

FMO6P

171115567

A

1.16

.1232

0.19

0.65

.0012

0.10

1

rs17565793

FMO6P

171116267

C

1.16

.1232

0.19

0.65

.0012

0.10

1

rs17623477

FMO6P

171116304

C

1.16

.1232

0.19

0.65

.0012

0.10

1

rs7051747

FMO6P

171116550

G

1.16

.1232

0.19

0.65

.0012

0.10

1

rs7066454

FMO6P

171116603

T

1.16

.1232

0.19

0.65

.0012

0.10

1

rs7063044

FMO6P

171116760

T

1.16

.1232

0.19

0.65

.0012

0.10

1

rs6608453

FMO6P

171117140

T

1.17

.1109

0.19

0.64

.0010

0.10

1

rs6608454

FMO6P

171117170

C

1.16

.1232

0.19

0.65

.0012

0.10

1

rs12726624

FMO1

171231630

G

0.67

.0004

0.13

1.03

.7385

0.47

1

rs17581251

FMO1

171232446

T

0.67

.0011

0.12

0.98

.8685

0.08

1

rs28360379_indel

FMO1

171234851

A

0.68

.0006

0.13

0.99

.8698

0.43

1

rs6674596

FMO1

171235088

T

0.67

.0004

0.14

1.01

.9325

0.46

1

rs13376631

FMO1

171235742

G

0.69

.0009

0.13

1.00

.9831

0.43

1

rs12094878

FMO1

171243863

C

0.69

.0012

0.14

1.04

.6315

0.47

1

rs12062692

FMO1

171245579

G

0.69

.0009

0.14

0.97

.7002

0.48

1

rs7539057

FMO1

171248614

A

0.70

.0012

0.14

0.95

.4840

0.42

1

rs742350

FMO1

171250044

T

0.69

.0012

0.14

1.03

.6911

0.46

1

rs12091482

FMO1

171251509

T

0.70

.0012

0.14

0.94

.4723

0.42

1

rs10399952

FMO1

171251663

G

0.69

.0011

0.14

0.95

.5037

0.42

1

rs10399602

FMO1

171251876

C

0.70

.0012

0.14

0.95

.4840

0.42

1

rs7519999

FMO1

171251958

G

0.70

.0012

0.14

0.95

.4840

0.42

1

rs1126692

FMO1

171252287

G

0.70

.0012

0.14

0.93

.3914

0.46

1

rs12092985

FMO1

171252537

A

0.70

.0012

0.14

0.95

.4840

0.42

1

rs10912714

FMO1

171253037

G

0.69

.0011

0.14

0.95

.4840

0.42

1

rs12059179

FMO1

171255346

T

0.70

.0012

0.14

0.91

.2620

0.39

Significant findings were given in bold.
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F I G U R E 1 Regional association plots of FMO1–FMO3–FMO6P genomic region based on (a) European Americans and (b) African Americans.
The blue dash lines are the −log10 (p-value) threshold used in our study(1.25 × 10−3)

decided by Bonferroni correction and thus were different for each

is located within a DNase hypersensitive area of assayed in multiple

dataset. We utilized .008 (.05/6) and .0025 (.05/20) as p-value thresh-

cell types. In addition, this variant is also located at a sequence motif

old for European American and African American dataset, respec-

region (HNF1). rs608453 has a Regulome DB score of 6. It is also lo-

tively. No significant signals were identified through haplotype-based

cated in a sequence motif (Cdx). No expression quantitative trait loci

analyses. The full results of haplotype-based analyses were summa-

(eQTL) or transcription factor binding related evidence was shown for

rized in Tables S7 and S8. Gene-wise association analyses mainly fo-

neither variants.

cused on rare and/or low-frequency variants in our dataset. Although
we have tried multiple analytical schema (combination of different
MAF threshold and region definitions), no significant association sig-

4 | DISCUSSION

nals were found in this analysis (Table S9).
As part of a large-scale targeted sequencing study focusing on

3.3 | Bioinformatics analysis

nicotine-dependent/nondependent smokers, our aim was to test the
hypothesis that genetic polymorphisms of FMO genes contribute to

Proteins that show evidence for interaction with proteins encoded by

the risk of nicotine dependence. The underlying rationale of this study

FMO1, FMO3, and FMO6P were extracted from STRING (Figs S1–S3,

is based on the fact that FMO genes are key genes of the nicotine me-

Tables S10–S12). STRING provided a combined score for each pro-

tabolism pathway (Bloom et al., 2013). FMO1 may play a role in nico-

tein pair as an evaluation of the relation between the two proteins,

tine metabolism and contributed to the nicotine level in brain organ

and this score was scaled from 0 to 1. Higher score indicates stronger

(Mackillop, Obasi, Amlung, McGeary, & Knopik, 2010), and FMO3 en-

relation between the two proteins. Both FMO1 and FMO3 have a

codes FMO 3, which can metabolize a small percentage of nicotine

strong relation with a variety of genes belonging to CYP gene families

into nicotine N′-oxide (Bloom et al., 2013). We studied both rare and

(with combined score greater than 0.9). FMO6P, however, as a pseudo

common variants in FMO1, FMO3, and FMO6P through large-scale

gene, only showed limited evidence to be related with PRSS16, which

targeted sequencing.

encodes a serine protease expressed exclusively in the thymus (with
combined score of 0.409).
We explored the top significant variants (rs6674596 and rs608453)

A number of common variants in FMO1 were identified to be significantly associated with nicotine dependence, and we noted that
there was an ethnic-specific pattern. We identified a cluster of signif-

in Regulome DB to investigate their potential biological significance.

icant variants in FMO1 in the European Americans. The most signifi-

Regulome DB has its own scoring system to measure the biological

cant variant was rs6674596 (p = .0004, OR = 0.67, MAF_EA = 0.135,).

significance of a variant. The range of the scores is from 1 to 6, and the

However, this significant result was not replicated in our African

smaller the score is, the more evidence that indicate this variant has

American dataset (p = .9325, OR = 1.01, MAF_AA = 0.463). The asso-

biological significance. rs6674596 has a Regulome DB score of 5, and

ciation signals for FMO1 have been reported by Hinrichs et al. (2011).

6 of 8
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Several significant SNPs reported in that study, including rs742350

SNP of FMO3. This suggests that the significant hit in FMO6P might

and rs1126692, were also identified to be significant in our study.

be a surrogate for some true underlying signal in FMO3. However, in

Considering both studies utilized COGEN samples, our results on the

our study, although some SNPs of FMO3 are indeed in complete LD

common SNPs basically replicated Hinrichs’ results. In addition to the

with the significant SNPs of FMO6P, the whole significant SNP cluster

significant findings in European American sample set, we also iden-

is located in the FMO6P region (Figure 1). On the other hand, if the

tified a set of significant variants located on gene FMO6P from the

signal we identified in FMO6P is not the surrogate for effects of SNPs

African American dataset (with the most significant SNP rs6608453,

in FMO3, but has an independent effect on nicotine dependence, then

p = .001, MAF_AA = 0.097). Just like significant variants were only

further research will be needed to clarify the underlying function of

identified in European Americans, this significant signal of FMO6P

FMO6P.

was only identified in African Americans, but failed to be replicated in

A major strength of our study is that, unlike most of the common

European Americans (p = .1109, OR = 1.17, MAF_EA = 0.192). No sig-

SNP-based association studies, we implemented a targeted sequenc-

nificant SNPs were identified from the combined sample set; although

ing technology for genotyping of our study subjects. This enables us to

in the combined samples set, the sample size almost doubled with a

consider both common and rare variants within the three gene regions.

correspondent increment in statistical power. The reasons behind this

Additionally, this study design enabled us to analyze both SNVs and

ethnic-specific pattern might be complex, and the most plausible one

indels which are often omitted in SNP-based study designs. However,

is differences in the regional LD structure between the two racial/eth-

there are also some limitations to this study that need to be noted.

nic groups. This difference might mean the surrogate SNPs miss the

First, we lack replication for our significant findings. The design using

signal created by the real underlying susceptible variants in a specific

two racial/ethnic groups in our study enabled us to use as the two

set of samples.

datasets as replication set for each other. However, significant findings

One major advantage of our targeted sequencing study is that we

in the European American dataset were not confirmed in the African

can examine every possible DNA variations in our targeted regions

American dataset. In addition, our sample size limited the statistical

and conducted association analysis thoroughly. However, in this study,

power to detect potential modest effects of SNPs. This is a common

we did not detect significant association between the rare variants and

challenge, especially when using study designs, such as targeted se-

nicotine dependence, although we systematically tried many combina-

quencing, which generate genotype data at many variants, leading to

tions of statistical methods, MAFs, region definitions, and sample sets.

multiple comparisons and corresponding stringent significance require-

The most significant rare variant set was identified for gene FMO1

ments. Future work to address this challenge would be to combine

with region definition of “gene region” and MAF < 0.01 in African

multiple sequenced datasets using meta-analysis, such approaches

Americans (p = .0636). The lack of significant findings for rare variants

have been productive for GWAS of complex traits and have yet to be

suggests that the significant associations for common SNPs are not

fully leveraged for sequencing studies and rare variant analyses.

simply surrogates for rare variant associations (synthetic associations;
Dickson, Wang, Krantz, Hakonarson, & Goldstein, 2010).

In summary, we tested the genetic effects of three FMOs genes
(FMO1, FMO3, and FMO6P) on nicotine dependence by performing

We found it interesting to examine the functional significance of

targeted sequencing on 2,852 nicotine-dependent and nondepen-

the significant common SNPs we identified. All of the significant com-

dent smokers. We performed both variant-level and gene/region-level

mon SNPs are located either in introns or outside the gene. Therefore,

analyses to examine the genetic association of rare, low-frequency,

if these significant common SNPs alter function, it is not by changing

and common variants within these region and nicotine dependence,

protein structure. The most significant SNP in FMO1, rs6674596, is

and both SNVs and indels. We identified significant association signals

located within a DNase hypersensitive area of assayed in multiple cell

for gene FMO1 and FMO6P. Replications of our finds in other eth-

types, and most of the regulatory regions and some promoter regions

nic groups were needed in the future. Most of the significant variants

tend to be DNase sensitive. This suggests that this SNP might have an

identified were SNPs located within intron regions or with unknown

effect on the expression of gene FMO1. Nevertheless, without further

functional significance, indicating a need for future work to under-

evidence from biological experiments, it is still too early to explain this

stand the underlying functional significance of these signals.

association signal.
FMO6P is a pseudo gene which means that this gene cannot be
properly expressed as a protein, and it is probably because it is unable to produce a full-length transcript (Hines et al., 2002). FMO6P is
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